Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Garcia

Child & Adolescent Psychiatry Northville, MI Medical Doctor

NPI 1184622136 CMS profile 234597

650 Griswold St, Northville, MI 48167

Open in the dashboard

General payments

$23,514

1,402 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Garcia of Northville, MI is reported in the CMS Open Payments database as having received $23,514 across 1,402 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,996 254
2024 General $4,319 251
2023 General $3,735 215
2022 General $3,222 177
2021 General $3,013 191
2020 General $2,113 139
2019 General $2,115 175

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Garcia
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Robert Garcia were reported at $4,996. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Robert Garcia Child & Adolescent Psychiatry median Middle half National median
2019 $2,115 $129 $42–$419 $163
2020 $2,113 $81 $28–$226 $114
2021 $3,013 $115 $31–$326 $132
2022 $3,222 $124 $40–$382 $149
2023 $3,735 $130 $45–$420 $160
2024 $4,319 $141 $42–$490 $164
2025 $4,996 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ITI, Inc. $2,237 122 payments
  2. Jazz Pharmaceuticals Inc. $1,840 69 payments
  3. Sunovion Pharmaceuticals Inc. $1,810 108 payments
  4. Otsuka America Pharmaceutical, Inc. $1,755 97 payments
  5. AbbVie, Inc. $1,684 108 payments
  6. Lundbeck LLC $1,425 119 payments
  7. Tris Pharma Inc $1,346 78 payments
  8. Alkermes, Inc. $1,187 50 payments
  9. Supernus Pharmaceuticals, Inc. $1,083 136 payments
  10. Axsome Therapeutics, Inc. $1,014 57 payments
  11. Other $8,132 458 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $22,947 1,396 payments
  2. Education $391 5 payments
  3. Consulting Fee $175 1 payment
Products named General payments · program years 2019–2025
  1. LATUDA $1,810 108 payments
  2. CAPLYTA $1,774 97 payments
  3. XYWAV $1,389 54 payments
  4. VRAYLAR $1,133 83 payments
  5. LYBALVI $1,122 46 payments
  6. REXULTI Psychiatry $1,042 58 payments
  7. Azstarys $962 57 payments
  8. REXULTI Psychiatry $866 74 payments
  9. Auvelity $817 45 payments
  10. Dyanavel XR $791 43 payments
  11. Other $17,368 1,018 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

2,566

Median for Psychiatry: 574

Drug cost

$214,589

Median for Psychiatry: $27,624

Branded share of claims

22.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 69 $97,936
Rexulti Brexpiprazole Brand 18 $38,874
Trintellix Vortioxetine Hydrobromide Brand 17 $17,163
Auvelity Dextromethorphan Hbr/Bupropion Brand 12 $13,213
Lurasidone Hcl Generic 19 $3,755
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 56 $3,647
Quetiapine Fumarate Generic 107 $3,287
Trazodone Hcl Generic 145 $2,644
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 26 $2,469
Bupropion Xl Bupropion Hcl Brand 139 $2,379

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$79,383

Medicare's payments for the services billed

Medicare patients

157

Average age 66

Services billed

871

105 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 67%
High blood pressure 64%
Arthritis 45%
Diabetes 25%
Chronic kidney disease 20%
Ischemic heart disease 19%
Osteoporosis 12%
COPD 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
$536 18 —
CAPLYTA
$417 — —
Qelbree
$345 — —
JORNAY PM
$326 — —
Azstarys
$300 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

1,402 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record